| Disease | A 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL. THE PARTICIPANTS WERE ALLOCATED RANDOMLY TO TREATMENT WITH EGB 761 TOTAL DOSAGE EITHER 240 (HIGH DOSE) OR 160 (USUAL DOSE) MG/DAY OR PLACEBO. OUTCOME
MEASURES INCLUDED NEUROPSYCHOLOGICAL TESTING DIGIT MEMORY SPAN VERBAL LEARNING, CLINICAL ASSESSMENT DEPRESSIVE MOOD, SELF-PERCEIVED HEALTH AND MEMORY STATUS, AND BEHAVIORAL ASSESSMENT. AN INTENTION-TO-TREAT ANALYSIS SHOWED NO EFFECT ON EACH OF
THE OUTCOME MEASURES FOR PARTICIPANTS WHO WERE ASSIGNED TO GINKGO COMPARED WITH PLACEBO FOR THE ENTIRE 24-WEEK PERIOD.
A COMMERCIAL PRODUCT, EGB-761, WAS USED. |